Prohance Multipack is a drug owned by Bracco Diagnostics Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 08, 2015. Details of Prohance Multipack's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5846519 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2015
(9 years ago) |
Expired
|
| US5474756 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(12 years ago) |
Expired
|
| US6143274 | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Prohance Multipack is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prohance Multipack's family patents as well as insights into ongoing legal events on those patents.
Prohance Multipack's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Prohance Multipack's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 08, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Prohance Multipack Generics:
There are no approved generic versions for Prohance Multipack as of now.
Alternative Brands for Prohance Multipack
Prohance Multipack which is used for enhancing visibility of tissues and organs during magnetic resonance imaging., has several other brand drugs using the same active ingredient (Gadoteridol). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bracco |
|
About Prohance Multipack
Prohance Multipack is a drug owned by Bracco Diagnostics Inc. It is used for enhancing visibility of tissues and organs during magnetic resonance imaging. Prohance Multipack uses Gadoteridol as an active ingredient. Prohance Multipack was launched by Bracco in 2003.
Approval Date:
Prohance Multipack was approved by FDA for market use on 09 October, 2003.
Active Ingredient:
Prohance Multipack uses Gadoteridol as the active ingredient. Check out other Drugs and Companies using Gadoteridol ingredient
Treatment:
Prohance Multipack is used for enhancing visibility of tissues and organs during magnetic resonance imaging.
Dosage:
Prohance Multipack is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 279.3MG/ML | INJECTABLE | Prescription | INJECTION |